Ritter Pharma engages AGP to explore strategic alternatives

Ritter Pharmaceuticals (NASDAQ:RTTR) has engaged Alliance Global Partners as a financial advisor to help the company evaluate strategic alternatives. 

The company is considering a variety of options, including an acquisition, merger, reverse merger, other business combination, sale of assets, licensing or other strategic transactions. 

On Sept. 12, the company reported that its Phase 3 clinical trial of RP-G28 for the treatment of lactose intolerance failed to demonstrate statistically significant symptom improvements compared to placebo.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.